Key Highlights

  • Shares traded at $0.130, up 8.33%, during the Trading session on 30 October 2026.
  • EBR submitted its application to the Therapeutic Goods Administration for inclusion of the WiSE System on the Australian Register of Therapeutic Goods.
  • The submission is expected to be assessed under a Priority Review Determination granted in April 2026, which reduces the target evaluation period.

EBR Systems Inc (ASX:EBR) shares traded at $0.130 during the trading session on 30 October 2026, rising 8.33%. The S&P/ASX 200 (ASX:XJO) stood at 8,973.00, up 0.91% or 81.20 points at 11:15 am. EBR is a Santa Clara, California developer of a wireless cardiac pacing system for heart failure, which it describes as the only wireless system that paces the left ventricle. Its submission to the Therapeutic Goods Administration was announced on 20 October 2026, ten days before the share move, so the two are discussed separately.

Latest Development: TGA Application (20 October 2026)

EBR announced that it had submitted its application to the Therapeutic Goods Administration for inclusion of the WiSE System on the Australian Register of Therapeutic Goods. The submission follows the Priority Review Determination granted in April 2026. The company said the submission is the next regulatory step towards potential market entry in Australia, which would extend its commercial footprint beyond the United States if approved.

The application is supported by the WiSE System's approval from the United States Food and Drug Administration. The company expects that, if the system is included on the register, it would be able to offer Australian clinicians and heart failure patients who have not benefited from conventional lead-based cardiac resynchronisation therapy a leadless left ventricular pacing option.

What Priority Review Involves

The Priority Review pathway is intended to accelerate the evaluation of breakthrough devices that address life-threatening or seriously debilitating conditions where there is a high unmet need. Under the pathway the target evaluation period is expected to be reduced through front-of-queue prioritisation.

The company states that the timing and outcome of the assessment remain subject to the regulator's review and cannot be guaranteed. The release also describes WiSE as an investigational device in most markets and currently available for sale only in the United States.

Sector Context

Cardiac resynchronisation therapy is an established treatment for some patients with heart failure, delivered through leads placed in the coronary sinus. Companies developing alternative pacing approaches must demonstrate clinical benefit and safety to regulators in each market. Regulatory timelines for medical devices in Australia depend on the classification and pathway a product uses.

Risks

The timing and outcome of the TGA assessment are uncertain and cannot be guaranteed. The device is investigational outside the United States, and its use in Australia would depend on approval and on clinical acceptance. The company's product sales remain limited to the United States, and the release does not provide Revenue figures for the Australian market. Forward-looking statements in the release carry the usual risks that actual results may differ.

What Lies Ahead

The company said it looks forward to working with the TGA through the Priority Review process. The next developments will be the regulator's assessment and any updates on timing, which the company says cannot be guaranteed.

The Bottom Line

EBR's shares rose 8.33% during the 30 October 2026 session, ten days after the company announced its TGA submission for the WiSE System. The outcome of the Priority Review assessment will determine whether the product can be offered in Australia, and the timing of that outcome has not been fixed.